drug · small molecule
imatinib mesylate
Phase 2updated 3mo agoby $IKT Inhibikase Therapeutics, Inc.🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for chronic myelogenous leukemia and 55 investigational indications.
targets
Bcr/Abl fusion proteinMast/stem cell growth factor receptor KitPlatelet-derived growth factor receptor betaTyrosine-protein kinase ABL1
all catalysts(0)
nothing on the calendar yet
Trials studying imatinib mesylate
- phase4Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
- phase1A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- phase2Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host
- phase1A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
- phase2Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
News(2)
- How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCODrs Camidge and Blanke discuss Dr Blanke's career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying.onclive · 3mo ago
- Dr Mauro on the Significance of Alternative TKI Formulations in CMLMichael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.onclive · 3mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that